Jasper Therapeutics(JSPR) - 2023 Q4 - Annual Results

About Briquilimab Exhibit 99.1 Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments REDWOOD CITY, Calif., March 4, 2024 – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter and year ended December 31, ...